Compare · CRL vs DKDCA
CRL vs DKDCA
Side-by-side comparison of Charles River Laboratories International Inc. (CRL) and Data Knights Acquisition Corp. (DKDCA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRL and DKDCA operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- CRL is the larger of the two at $13.27B, about 88.0x DKDCA ($150.9M).
- CRL has hit the wire 5 times in the past 4 weeks while DKDCA has been quiet.
- CRL has more recent analyst coverage (25 ratings vs 0 for DKDCA).
- Company
- Charles River Laboratories International Inc.
- Data Knights Acquisition Corp.
- Price
- -
- -
- Market cap
- $13.27B
- $150.9M
- 1M return
- -4.26%
- -
- 1Y return
- +78.64%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- 2021
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 0
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Latest CRL
- Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
- Charles River Laboratories to Present at Morgan Stanley and Baird Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by Charles River Laboratories International Inc.
- Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
- Director Foster James C exercised 33,561 shares at a strike of $199.42 and sold $10,068,300 worth of shares (33,561 units at $300.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Girshick Birgit gifted 528 shares, decreasing direct ownership by 1% to 35,485 units (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M exercised 2,039 shares at a strike of $194.12 and sold $599,711 worth of shares (2,039 units at $294.12) as part of a pre-agreed trading plan (SEC Form 4)
- Director Andrews Nancy C exercised 573 shares at a strike of $164.30 and sold $163,443 worth of shares (573 units at $285.24) (SEC Form 4)
- Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
- Chief Executive Officer Girshick Birgit exercised 6,500 shares at a strike of $179.66 and sold $1,819,350 worth of shares (6,500 units at $279.90) as part of a pre-agreed trading plan (SEC Form 4)
Latest DKDCA
- SEC Form SC 13G/A filed by Data Knights Acquisition Corp. (Amendment)
- Data Knights Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form SC 13G/A filed by Data Knights Acquisition Corp. (Amendment)
- SEC Form S-1 filed by Data Knights Acquisition Corp.
- Data Knights Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Data Knights Acquisition Corp.
- New insider Casey Paul claimed ownership of 599,172 shares (SEC Form 3)
- New insider Kosasa Thomas claimed ownership of 4,952,409 shares (SEC Form 3)
- SEC Form NT 10-Q filed by Data Knights Acquisition Corp.
- Data Knights Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status